Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in Previously Untreated Metastatic Pancreatic Cancer
NCT00005843Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2000
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Primary endpoints: Safety and Tolerability, Objective Response Rate and 2 more. Started May 2000; status: completed.
02
Drugs
tipifarnib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00005843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005843.